Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EPS (Basic) (2016 - 2026)

Anika Therapeutics has reported EPS (Basic) over the past 17 years, most recently at -$0.37 for Q1 2026.

  • Quarterly EPS (Basic) fell 32.14% to -$0.37 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.8 through Mar 2026, down 8.11% year-over-year, with the annual reading at -$0.7 for FY2025, 16.67% down from the prior year.
  • EPS (Basic) was -$0.37 for Q1 2026 at Anika Therapeutics, down from $0.12 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $1.74 in Q4 2024 and troughed at -$4.3 in Q4 2023.
  • The 5-year median for EPS (Basic) is -$0.29 (2022), against an average of -$0.5.
  • Year-over-year, EPS (Basic) crashed 1164.71% in 2023 and then skyrocketed 140.47% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.34 in 2022, then crashed by 1164.71% to -$4.3 in 2023, then skyrocketed by 140.47% to $1.74 in 2024, then crashed by 93.1% to $0.12 in 2025, then tumbled by 408.33% to -$0.37 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's EPS (Basic) are -$0.37 (Q1 2026), $0.12 (Q4 2025), and -$0.22 (Q3 2025).